Enlivex Therapeutics (ENLV) Appoints Andrew Singer to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Enlivex Appoints Andrew Singer to its Board of Directors
April 17, 2023 8:01 AM EDTMr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategyFormer EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells Fargo Securities and RBC Capital MarketsLed financing, partnering and M&A biopharmaceutical transactions in excess of $13 billion
Nes-Ziona, Israel, April 17, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Andrew Singer to its Board of Directors. Mr. Singer brings more than 25 years of experience in biotechnology,... More
